NCT02055976 - Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Hypercholesterolemia

Interventions

DRUG

Bococizumab (PF-04950615;RN316)

Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week

DRUG

Bococizumab (PF-04950615;RN316)

Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week

DRUG

Bococizumab (PF-04950615;RN316)

Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week

DRUG

Placebo

Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week

DRUG

Ezetimibe

Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)

DRUG

Bococizumab (PF-04950615;RN316)

50 mg Q14D SC for 16 week

DRUG

Bococizumab (PF-04950615;RN316)

100 mg Q14D SC for 16 week

DRUG

Bococizumab (PF-04950615;RN316)

150 mg Q14D SC for 16 week

DRUG

Placebo

Placebo Q14D SC for 16 week

Trial Locations (9)

371-0022

Maebashi Hirosegawa Clinic, Maebashi

232-0064

Yokohama Minoru Clinic, Yokohama

565-0853

Heishinkai Medical Group Incorporated OCROM Clinic, Suita

101-0041

Meiwa Hospital, Chiyoda-ku

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

160-0022

Heishinkai Medical Group Incorporated ToCROM Clinic, Shinjuku-ku

162-0053

Clinical Research Hospital Tokyo, Shinjuku-ku

169-0072

Oda Clinic, Shinjuku-ku

171-0014

Sekino Hospital, Toshima-ku